glutathione binding to iron Controlling entry into mitochondria: potential roles for SLC25A39 in health and (treatment of) disease Glutaredoxin catalysis requires two distinct

A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer's disease mice

A3 receptor antagonists lower IOP by preventing adenosine-induced activation of Cl- channels in ciliary epithelial cells, while A2A receptor activation in Schlemm's canal cells can have bidirectional effects on IOP (90, 92)

Despite completing multiple phase III trials with positive data on testosterone and fertility endpoints, the branded formulation (Androxal) did not receive FDA approval, partly due to disagreements about the appropriate clinical indication and comparator design

Author Affiliations: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts (Matta, Tanev, Stern)

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)